| Project/Area Number |
03670636
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
MIZUNO Isamu Nagoya City University Medical School, Lecturer., 医学部, 講師 (20157506)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOTSUYANAGI Toshihisa Nagoya City University faculty of pharmaceuticl Sciences Professer., 薬学部, 教授 (40080189)
市野 達夫 名古屋市立大学, 医学部, 助手 (60223103)
|
|---|
| Project Period (FY) |
1991 – 1993
|
| Project Status |
Completed (Fiscal Year 1993)
|
| Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1993: ¥200,000 (Direct Cost: ¥200,000)
Fiscal Year 1992: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1991: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | Hydroxyapatite / carboplatin / rntraperitoneal administration / drug carrier / AH-130 / 水酸アパタイト |
|---|
| Research Abstract |
Hydrosyapatite(HAp) has excellent compatibility wity human sissues and is used in percutameous devices. as well as in orthopedic and dental procedures. Thedrug carrier HAp particle has ores 23-59 mu m in diameter with surface area of 2.5m^2/g. The drug delivery system carboplatin-loaded Hap particles (HAp-CBDCA) was contained 200mg HAp and 4mg CBDCA.The efficacy of intraperitoneal administration of HAp-CBDCA was wxplored using a Donryu rat model of tumor cell AH-130 carcinomatous peritonitis. The pharmacokinetics of CBDCA following intraperitoneal administration of HAp-CBDCA was studied. Serum levels of CBDCA were higher in HAp-CBDCA group wity the free CBDCA group from post-drug administration hour 6 unil hour 24. We found that intraperitoneal administration of HAp-CBDCA was effective in prolongation of rats bearing AH-130 in peritoneal cavity. These results demonstrate the effecacy of HAp particles as carrier for anticancer drugs, with ultimate improvement in overall survival.
|
